Drug Type Antibody drug conjugate (ADC), Therapeutic radiopharmaceuticals |
Synonyms- |
Target |
Action modulators, agonists |
Mechanism PD-1 modulators(Programmed cell death protein 1 modulators), TP53INP2 agonists(tumor protein p53 inducible nuclear protein 2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 25 May 2023 | |
Neoplasms | Preclinical | United States | 25 May 2023 |